Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?

详细信息    查看全文

• 作者：George R. Dakwar^a ; Molood Shariati^a ; Wouter Willaert^b ; ^c ; Wim Ceelen^b ; ^c ; Stefaan C. De Smedt^a ; ^{stefaan.desmedt@ugent.be} ; Katrien Remaut^a ; ^c ; ^{Katrien.Remaut@ugent.be}
• 关键词：CRS ; cytoreductive surgery ; HA ; hyaluronic acid ; IP ; intraperitoneal ; IPEC ; intraperitoneal chemotherapy ; HIPEC ; hyperthermic intraperitoneal chemoperfusion ; IFP ; interstitial fluid pressure ; MDR ; multi drug resistance ; MPs ; microparticles ; NPs ; nanoparticles ; PTX ; paclitaxel ; PC ; peritoneal carcinomatosis ; PIPAC ; Pressurized IntraPeritoneal Aerosol Chemotherapy ; VEGF ; vascular endothelial growth factor
• 刊名：Advanced Drug Delivery Reviews
• 出版年：2017
• 出版时间：1 January 2017
• 年：2017
• 卷：108
• 期：Complete
• 页码：13-24
• 全文大小：1509 K
• 卷排序：108

文摘

Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal carcinomatosis (PC). Over the past decade, a lot of effort has been put both in the academia and clinic in developing IP therapeutic approaches that maximize local efficacy while limiting systemic side effects. Also nanomedicines are under investigation for the treatment of tumors confined to the peritoneal cavity, due to their potential to increase the peritoneal retention and to target drugs to the tumor sites as compared to free drugs. Despite the progress reported by multiple clinical studies, there are no FDA approved drugs or formulations for specific use in the IP cavity yet. This review discusses the current clinical management of PC, as well as recent advances in nanomedicine-based IP delivery. We address important challenges to be overcome towards designing optimal nanocarriers for IP therapy in vivo.